This filing contains no new financial information or material events. Monitor the upcoming proxy statement and any subsequent 8-Ks for updates on the iopofosine I 131 NDA timeline, which is the primary catalyst for this pre-revenue biotech.
Price Chart
Executive Summary
Cellectar Biosciences filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive officers, security ownership, related transactions, and audit fees) that was previously omitted pending a proxy statement. No financial statements were amended, no restatements were made, and no changes were made to the original financial results or disclosures. This is a routine administrative filing with no material financial impact.
Key Facts
- Amendment adds Part III Items 10, 12, 13, and 14 (director/officer info, beneficial ownership, related transactions, audit fees) that were omitted from the original 10-K filed March 4, 2026.
- No financial statements, no restatements, and no changes to any previously reported financial data.
- Auditor remains Deloitte & Touche LLP (Morristown, NJ). Audit fees declined from $1,883,941 in FY2024 to $878,391 in FY2025.
- As of April 29, 2026, there were 4,240,129 common shares outstanding. Directors and officers as a group beneficially own 4.68% of common stock.
- The company disclosed a prior restatement of FY2022 and FY2023 financials, with FY2024 audit fees including costs related to that restatement.
Financial Impact
No new financial data. Audit fees fell from $1,883,941 (FY2024) to $878,391 (FY2025).
Risk Factors
- Pre-revenue clinical-stage biotech with $11M market cap — high cash burn risk.
- Prior restatement of FY2022 and FY2023 financials indicates historical accounting control issues.
- Heavy reliance on iopofosine I 131 regulatory approval for any future value inflection.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001104659-26-053090 |
| Document: clrb-20251231xex31d2.htm | 0001104659-26-053090 |
| Document: clrb-20251231xex31d4.htm | 0001104659-26-053090 |
| Document: 0001104659-26-053090-index-headers.html | 0001104659-26-053090 |
| Document: 0001104659-26-053090-index.html | 0001104659-26-053090 |
| Document: 0001104659-26-053090.txt | 0001104659-26-053090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers